Oryzon Genomics SA
MAD:ORY
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oryzon Genomics SA
Sachanlagen brutto
Oryzon Genomics SA
Sachanlagen brutto Peer-Vergleich
Oryzon Genomics SA
Kurzansicht
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
Auch interessant
Wie hoch ist Sachanlagen brutto von Oryzon Genomics SA?
Sachanlagen brutto
380.1k
EUR
Laut Finanzbericht vom Dec 31, 2025 beträgt Sachanlagen brutto von Oryzon Genomics SA 380.1k EUR.
Wie hoch ist die Wachstumsrate von Sachanlagen brutto bei Oryzon Genomics SA?
Sachanlagen brutto CAGR 10J
-8%
Im letzten Jahr lag das Wachstum von Sachanlagen brutto bei 7%. Die durchschnittlichen jährlichen Wachstumsraten von Sachanlagen brutto bei Oryzon Genomics SA lagen bei -15% über die letzten drei Jahre , -10% über die letzten fünf Jahre und -8% über die letzten zehn Jahre .
